Publications by authors named "L Antonuzzo"
Article Synopsis
- Hyponatremia is known to indicate survival chances in metastatic non-small cell lung cancer (mNSCLC), but the effects of normal sodium levels had not been previously studied until this research.
- The study involved 88 mNSCLC patients treated with immune checkpoint inhibitors (ICIs) and analyzed how sodium levels affected their treatment responses and overall survival.
- Results showed that patients with sodium levels ≥140 mEq/L had significantly better progression-free survival (7.0 months vs. 2.1 months) and overall survival (15.6 months vs. 6.8 months), suggesting low sodium levels are linked to worse outcomes in mNSCLC.
Article Synopsis
- In the TOPAZ-1 trial, patients with biliary tract cancers (BTC) who had recurrence within 6 months of surgery were excluded, which often happens in practice. This study looked into the effectiveness of cisplatin-gemcitabine-durvalumab (CGD) in patients who did experience early recurrence.
- The study enrolled 178 BTC patients who had surgery and then underwent treatment with CGD after experiencing either early or late disease recurrence. Key goals were to measure overall survival (OS) and progression-free survival (PFS).
- Results showed no significant differences in OS and PFS between early and late relapse groups, suggesting CGD is effective regardless of when the cancer
Colorectal cancer (CRC) represents a global health threat, standing as the second leading cause of cancer-related death worldwide. Targeted therapies brought new hope for the metastatic stage, which historically bore a very poor prognosis. Human epidermal growth receptor 2 (HER2) overexpression concerns about 5 % of the metastatic CRC (mCRC) patients, including both gene amplifications and point mutations.
View Article and Find Full Text PDFBackground: Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may improve outcomes.
Methods: In this phase 3, open-label, randomized trial, we assigned, in a 1:1 ratio, cisplatin-eligible patients with muscle-invasive bladder cancer to receive neoadjuvant durvalumab plus gemcitabine-cisplatin every 3 weeks for four cycles, followed by radical cystectomy and adjuvant durvalumab every 4 weeks for eight cycles (durvalumab group), or to receive neoadjuvant gemcitabine-cisplatin followed by radical cystectomy alone (comparison group).